TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
- Donate $5 to support research led by The EHE Foundation.
- Challenge 5 people to donate $5 and challenge 5 other people.
Copy and paste this message: "I'm doing the 5 for 5 Challenge for EHE! Are you up for the challenge? Just donate $5 at FightEHE.org and challenge 5 people to do the same." Spread the word and keep the chain of hope going!
Amy is living with progressing epithelioid hemangioendothelioma (EHE). Diagnosed in 2010, she has had a challenging journey, including a liver transplant, removal of lung tumors, and various systemic therapies.
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
The EHE Foundation Announces Grant Funding of $307,400 to Advance Research and Find Treatments for EHE
We are pleased to announce The EHE Foundation’s 2024 Research Grants Program awards, totaling $307,400, as part of our ongoing commitment to advance our mission to find effective treatments and a cure for EHE. Made possible by 2023 Giving Tuesday gifts, these grants support novel translational research projects that aim to identify and accelerate the […]
Read More
Making a Donation vs. Fundraising for The EHE Foundation: What’s the Difference?
At The EHE Foundation, we are committed to finding a cure for epithelioid hemangioendothelioma (EHE), an ultra-rare and potentially aggressive cancer that affects one in a million people. Every contribution helps us advance groundbreaking research, support patients, and foster collaboration among clinicians and researchers worldwide. There are two impactful ways you can support our mission: […]
Read More
Scientific & Medical Advisory Board Collaborates to Improve Outcomes for People Living with EHE
On September 10, 2024, The EHE Foundation held a virtual meeting of our Scientific & Medical Advisory Board (SMAB). The meeting aimed to welcome new members, review current research projects, and discuss future needs and goals to advance EHE research. The meeting began with a warm welcome to new members of the SMAB: Tom Chen, […]
Read More
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and is Down-regulated by Sirolimus Through ATF4/ATF5 Suppression
Drs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]
Read More
Harnessing Cyclin-dependent Kinase Inhibitors to Gain Mechanistic Insight Into the Regulation of the TAZ-CAMTA1 Fusion Protein
Ajay Pobbati, PhD, Brian Rubin, MD, PhD, and colleagues at the Cleveland Clinic published their findings from the study “CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma” in Clinical Cancer Research, September 13, 2024. This study, funded in part by a grant from The EHE Foundation, provides a strong rationale for investigating […]
Read More
EHE Community Connections for Caregivers: Anticipatory Grief
As a caregiver, it can be hard to not think about the future and what it may or may not hold. In doing so, it is common for caregivers to experience anticipatory grief, in which we mourn the loss of our loved one while they are still here as well as grieve the future that […]
Read More
Scanxiety
What is scanxiety? Scanxiety describes the apprehension felt by people with cancer as they wait for their next scan. It’s a form of anticipatory anxiety. Scans are like emotional roulette. You’re trying really hard not to worry about the unknown, but your body has other plans. Recognizing the Signs of Scanxiety Symptoms of scanxiety vary […]
Read More
Planned Ikena Oncology Clinical Trial to Include EHE Patients
The planned Phase 1 clinical trial includes patients with tumor types with a high frequency of Hippo pathway alterations, including NF2-deficient malignant mesothelioma and some soft tissue sarcomas with YAP/TAZ genetic fusions, including Epithelioid Hemangioendothelioma (EHE), a rare form of soft tissue sarcoma that has a significant unmet medical need with no currently approved therapy […]
Read More
The Pledge: Edition 27, Q4 – Oct-Dec, 2021
Together, the US, UK, and Australia EHE foundations team up to strengthen the force against EHE. This group provides a quarterly update, which is led by the UK and includes research news, patient and fundraising stories, and much more! Click here to view the most recent edition of our online EHE newsletter, The Pledge.
Read More